MONITORING OF EFFECTIVENESS OF SPIRONOLACTONE THERAPY AND ITS COMBINATIONS WITH FUROSEMIDE TO LIVER CIRRHOSIS AND ASCITES IN RSUP H. ADAM MALIK MEDAN

Authors

  • Elliya Siswanti Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia.
  • Urip Harahap Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia.
  • Juwita Sembiring Department of Internal Medicine, Division of Gastroentero Hepatology, Faculty of Medical, University of Sumatera, Utara/Haji Adam Malik General Hospital, Medan, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11s1.26596

Keywords:

Cirrhosis, Ascites, Spironolactone, Its combinations with furosemide

Abstract

Objectives: Spironolactone and furosemide are diuretics used to treat liver cirrhosis with ascites, but not case studies have been found to distinguish the effects of spironolactone and its combination with furosemide in cases of cirrhosis accompanied by ascites. This study aims to determine the effectiveness of spironolactone therapy and its combination with furosemide to liver cirrhosis patients accompanied ascites.

Methods: This research was done by cross-sectional prospective method. 26 patients in RSUP H Adam Malik Medan for 3 months were divided into two groups. The first group of nine patients, age between 39 and 65 years, was given spironolactone. The second group of 17 patients, age between 20 and 81 years, was given spironolactone combined with furosemide. The sample data were analyzed with statistics using Mann–Whitney U-test, SPSS program version 22.

Result: Based on Mann–Whitney U statistic test, the value of Asymp. significance (2-tailed) 0.435 for urine Na/K at time, and Asymp. significance value (2-tailed) 0.628 24 h urine sodium examination, based on the value, it was concluded that there was no significant difference between spironolactone with its combination with furosemide. Even though the significant value were 0.628 mEq and 0.435 mEq (p>0.05).

Conclusion: This study showed that the combination of spironolactone with furosemide was better than compared to spironolactone. Although there was not statistically significant difference if seen from the comparison of 24 h of urine sodium value with a normal value of 78 mEq.

Downloads

Download data is not yet available.

References

Ali SH, Nurul AH, Lauretius LA, Sjaifoellah N. ???. 1st ed. ???: Jaya Badi; 2007. p. 335-65.

Cheney CP, Goldberg EM, Chopra S. Cirrhosis and portal hypertension: An overview. Handbook of Liver Disease. 2nd ed. Philadelphia: Churchill Livingstone; 2013. p. 96.

Wolf DC. Cirrhosis of the Liver. Available from: http://www.emedicine. com/med/topic3183.htm. [Last accessed on 2015 Oct 08].

Dhini S. Accuracy of the Na/K ratio in time to 24-hour urine sodium in assessing diuretic sensitivity in patients with liver cirrhosis with ascites in RSUP. H Adam Malik Medan 2015

Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure:Part I- Diagnosis and evaluation. USA: American Family Physic; 2006. p. 745, 756-62.

Sudoyo, Aru W, Bambang S, Idrus A, Marcellus SK, Siti S. Science of Internal Medicine. 5th ed. Jakarta: Internal Publishing; 2009. p. 668-79.

Raosoft. 2013. Simple Size Calculator. Available from: http://www. Raosoft.Com/samplesize. Html. [Last accessed on 2017 Oct 05].

Yaswir R, Ferawati I. Andalas Health Journal. Padang: University of Andalas; 2015. p. 23-32.

Pamungkas RA., Nusdin, Sudarman B. Statistics for Nurses and Health. Jakarta: Trans Media Info Publisher; 2016. p. 67.

Sofi A. Stop Cancer. First Printing. Yogyakarta: Publisher Istana Media; 2015. p. 123-4.

Sulistia GG, Rianto S, Frans SD, Nafrialdi P. Pharmacology and Therapeutics. Issue 4. New York: New Style; 1995. p. 380-99.

Muti F, Annisa. Evaluate the effectiveness of diuretics in liver cirrhosis patients with ascites complications treated in DR hospital. Yogyakarta: Sardjito; 2011. p. 23-4.

Published

26-04-2018

How to Cite

Siswanti, E., U. Harahap, and J. Sembiring. “MONITORING OF EFFECTIVENESS OF SPIRONOLACTONE THERAPY AND ITS COMBINATIONS WITH FUROSEMIDE TO LIVER CIRRHOSIS AND ASCITES IN RSUP H. ADAM MALIK MEDAN”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 13, Apr. 2018, pp. 159-61, doi:10.22159/ajpcr.2018.v11s1.26596.

Issue

Section

Original Article(s)

Most read articles by the same author(s)

<< < 1 2 3